サンプル依頼リスト カート
  • English
  • Korean
表紙：次世代免疫療法の世界市場-2023年～2030年
市場調査レポート
商品コード
1374775

次世代免疫療法の世界市場-2023年～2030年

Global Next Generation Immunotherapies Market -2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
次世代免疫療法の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の次世代免疫療法市場は、そのダイナミクスに影響を与える様々な要因によって、長年にわたって大きな成長と変貌を遂げてきました。長年にわたる腫瘍学の臨床経験から、がん免疫療法がこれまでにない治療上の利点をもたらすことが明らかになっています。残念なことに、今日、免疫療法の恩恵を受けている患者はごく一部です。最近では、RNA脂質ナノ粒子が免疫活性化のための万能の道具となっています。

特に新興経済諸国における政府との提携、投資、研究開発は、モノクローナル抗体や免疫チェックポイント阻害剤のような新規医薬品の利用を引き続き促進し、世界の次世代免疫療法市場を押し上げると思われます。それぞれの革新的な免疫療法は、複数の研究者によって開発され、現在研究が進められています。

市場促進要因：市場抑制要因

共同研究や買収の増加

新興経済諸国では、高額の投資、所得水準、インフラ整備を背景に、ヘルスケア分野の改善が急速に進んでいます。次世代免疫療法に対する需要が高まっている国もあります。さまざまな国間での共同研究、買収、技術的進歩を伴う製品の発売は、市場の成長を促進する重要な要因です。

2022年11月17日、CytomX Therapeutics, Inc.とRegeneron Pharmaceuticals, Inc.は、CytomX社のProbody有用プラットフォームとRegeneron社のVeloci-Bi二重特異性抗体開発プラットフォームを用いて、条件付き活性化治験用二重特異性がん治療薬を開発するため、提携し、ライセンシング契約に合意しました。戦略的には、CytomX社の生物学的マスキング技術を活用し、腫瘍の微小環境においてプロテアーゼによって活性化されるまで休眠状態にあるリジェネロン社の探索的二重抗体の創製を目指します。

さらに、2022年6月2日、Immatics N.V.とBristol Myers Squibb社は、戦略的パートナーシップを拡大し、多数の同種標準TCR-Tおよび/またはCAR-T製品の開発を模索しています。イマティクスN.V.は臨床段階のバイオ医薬品企業であり、T細胞を誘導するがん免疫療法の発見と創製に取り組んでいます。

さらに、いくつかの研究目的での新規技術の利用や製品の発売が増加しています。がん症例の増加と革新的な治療製品開発のための研究の増加は、次世代免疫療法市場の成長を促進する主な要因です。

免疫療法に伴う副作用

免疫療法の副作用として、免疫系が健康な細胞を攻撃することがあります。「免疫関連の副作用」は、副作用として知られることもあります。このような副作用は、治療期間中のどの時点でも起こりうるし、時には免疫療法終了後にも起こりうる。免疫療法には様々な副作用が伴います。免疫チェックポイント阻害薬の副作用として、免疫細胞だけでなく、健康な身体組織も免疫細胞によって攻撃されることがよくあります。このプロセスは炎症として知られています。

CAR T細胞治療の典型的な副作用は感染症です。感染と闘う免疫系の能力が低下している可能性があるため、点滴の直後に頻繁に起こります。発熱、吐き気、疲労感、頭痛、脱力感、全体的な不快感などはすべて感染の徴候です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 共同研究や買収の増加
      • 技術的進歩と開発の高まり
    • 抑制要因
      • 免疫療法に伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • SWOT分析
  • 特許分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 免疫療法タイプ別

  • モノクローナル抗体
  • 免疫チェックポイント阻害薬
  • 非特異的免疫療法
    • サイトカイン
    • カルメット菌（BCG）
  • 抗体薬物複合体
  • 細胞療法
    • T細胞療法
    • B細胞療法
  • その他

第8章 投与経路別

  • 経口
  • 非経口

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Regeneron Pharmaceuticals Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Boehringer Ingelheim International GmbH
  • MacroGenics, Inc.
  • Mereo Biopharma Group PLC
  • Sorrento Therapeutics
  • BioNTech SE

第13章 付録

目次
Product Code: PH7175

Overview

The global next generation immunotherapies market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Years of oncology clinical experience have shown that cancer immunotherapy offers unheard-of therapeutic advantages. Tragically, only a small percentage of patients benefit from immunotherapies today. Recently, RNA lipid nanoparticles have become versatile instruments for immune activation.

Government partnerships, investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like monoclonal antibodies or immune checkpoint inhibitors and boost the global next generation immunotherapies market. The respective innovative immunotherapies are being developed by several researchers and currently are being studied.

Market Dynamics: Drivers & Restraints

Growing collaborations and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for next generation immunotherapies owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On November 17, 2022, in order to develop conditionally-activated investigational bispecific cancer therapies using CytomX's Probody helpful platform and Regeneron's Veloci-Bi bispecific antibody development platform, CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. collaborated and agreed to a licensing agreement. Strategically, the team aims to create exploratory Regeneron bispecifics that are dormant until activated by proteases in the microenvironment of tumors by utilizing CytomX's biologic masking techniques.

Additionally, on June 2, 2022, Immatics N.V. and Bristol Myers Squibb have broadened their strategic partnership to explore the development of numerous allogeneic standard TCR-T and/or CAR-T products. Immatics N.V. is a clinical-stage biopharmaceutical business engaged in the discovery and creation of T cell-redirecting cancer immunotherapies.

Furthermore, the rising utilization of novel technology and product launches for the several research purposes. Rising oncology cases and increasing research for innovative treatment product development will be a major factor driving the growth of the next generation immunotherapies market.

Side effects associated with the immunotherapy

The immune system may assault healthy cells as a side effect of immunotherapy. "Immune-related adverse effects," sometimes known as side effects, may result from this. These could occur at any point over the course of the therapy or occasionally even after finishing immunotherapy. Immunotherapy comes with a variety of adverse effects. Immune cells as well as healthy bodily tissues are frequently attacked by immune cells as immune checkpoint inhibitor side effects. This process is known as inflammation.

A typical side effect of CAR T-cell treatment is infection. They frequently occur immediately after the infusion because the immune system's ability to combat infections may be compromised. Fever, nausea, exhaustion, headaches, weakness, and an overall sensation of discomfort are all signs of infection.

Segment Analysis

The global next generation immunotherapies market is segmented based on immunotherapy type, route of administration, distribution channel and region.

Monoclonal Antibodies segment accounted for approximately 32% of market share

Immune system proteins known as monoclonal antibodies are produced in a laboratory. The body naturally produces antibodies, which assist the immune system in identifying pathogenic microorganisms like bacteria and viruses and marking them for eradication. Cancer treatment frequently makes use of monoclonal antibodies.

As a form of targeted cancer therapy, they are created to interact with particular targets. Certain monoclonal antibodies are also used in immunotherapy because they assist the body fight cancer by activating the immune system. As an illustration, certain monoclonal antibodies label cancer cells to help the immune system more easily identify and eliminate them.

On December 21, 2022, the U.S. Food and Drug Administration (FDA) has approved Genentech's Actemra (tocilizumab) intravenous (IV) for the management of COVID-19 in being treated adult patients who receive systemic corticosteroids and need additional oxygen, non-invasive and invasive mechanical ventilation, or oxygenation through extracorporeal membranes (ECMO). Actemra, the first monoclonal antibody approved by the FDA to treat COVID-19, is advised for use as a single, 60-minute IV infusion.

Geographical Penetration

North America accounted for around 38% of market share in 2022

Due to the rising need for next generation immunotherapies in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for next generation immunotherapies.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of medicines, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of next generation immunotherapies market share of this region. The market in this area is growing as people become more aware of various novel approved therapies. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global next generation immunotherapies market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for next generation immunotherapies in the U.S. United States have been proactive in executing several initiatives or researches, stimulating next generation immunotherapies demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global next generation immunotherapies market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various therapies, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for next generation immunotherapies. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global next generation immunotherapies market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative immunotherapy type.

Key Developments

  • On September 11, 2023, The U.S. Food and Drug Administration (FDA) has authorized the supplemental biologics license application for people 12 years of age and older and granted emergency use authorization for people 6 months to 11 years of age for the companies' monovalent COVID-19 vaccine modified for Omicron XBB.1.5. This was announced by Pfizer Inc. and BioNTech SE.
  • On January 9, 2023, in order to find and develop next-generation cancer medicines that will significantly address unmet patient needs, 3T Biosciences and Boehringer Ingelheim have engaged into an strategic partnership and licensing agreement. Boehringer Ingelheim's two-pronged investigation approach combining cancer cell-directed and immune cell-targeting compounds will be combined with 3T Biosciences' unparalleled 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform, further strengthening the company's pipeline.
  • On June 4, 2021, in order to develop novel cell-based therapeutics using natural killer ("NK") cells generated from induced pluripotent stem cells ("iPSCs"), Sorrento Therapeutics, Inc. has entered into another collaborative agreement with research groups affiliated with the NextGenNK Competence Center at the Department of Medicine, Huddinge, Karolinska Institutet in Stockholm, Sweden. The Competence Center for the creation of next-generation cancer immunotherapies based on NK cell (referred to as "NextGenNK") is a partnership between Sorrento and KI.

Competitive Landscape

The major global players in the market include: Regeneron Pharmaceuticals Inc., AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, MacroGenics, Inc., Mereo Biopharma Group PLC, Sorrento Therapeutics and BioNTech SE.

Why Purchase the Report?

  • To visualize the global next generation immunotherapies market segmentation based on immunotherapy type, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of next generation immunotherapies market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global next generation immunotherapies market report would provide approximately 61 tables, 59 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Immunotherapy Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing collaborations and acquisitions
      • 4.1.1.2. Rising technological advancements and developments
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the immunotherapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. SWOT Analysis
  • 5.6. Patent Analysis
  • 5.7. Russia-Ukraine War Impact Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Immunotherapy Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
    • 7.1.2. Market Attractiveness Index, By Immunotherapy Type
  • 7.2. Monoclonal Antibodies*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Immune Checkpoint Inhibitors
  • 7.4. Non-specific Immunotherapies
    • 7.4.1. Cytokines
    • 7.4.2. Bacillus Calmette-Guerin (BCG)
  • 7.5. Antibody Drug Conjugate
  • 7.6. Cellular Therapy
    • 7.6.1. T-Cell Therapy
    • 7.6.2. B-Cell Therapy
  • 7.7. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Immunotherapy Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Regeneron Pharmaceuticals Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. AstraZeneca
  • 12.3. Bristol-Myers Squibb Company
  • 12.4. Pfizer Inc.
  • 12.5. Gilead Sciences, Inc.
  • 12.6. Boehringer Ingelheim International GmbH
  • 12.7. MacroGenics, Inc.
  • 12.8. Mereo Biopharma Group PLC
  • 12.9. Sorrento Therapeutics
  • 12.10. BioNTech SE

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us